ES2548575T3 - Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados - Google Patents
Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados Download PDFInfo
- Publication number
- ES2548575T3 ES2548575T3 ES10817918.5T ES10817918T ES2548575T3 ES 2548575 T3 ES2548575 T3 ES 2548575T3 ES 10817918 T ES10817918 T ES 10817918T ES 2548575 T3 ES2548575 T3 ES 2548575T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- independently
- impurities
- xanten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000003732 xanthenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 4
- 239000012535 impurity Substances 0.000 abstract 4
- 150000002500 ions Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24370109P | 2009-09-18 | 2009-09-18 | |
| US243701P | 2009-09-18 | ||
| PCT/US2010/049341 WO2011035161A1 (en) | 2009-09-18 | 2010-09-17 | Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5'7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2548575T3 true ES2548575T3 (es) | 2015-10-19 |
Family
ID=43757167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10817918.5T Active ES2548575T3 (es) | 2009-09-18 | 2010-09-17 | Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8530675B2 (en:Method) |
| EP (1) | EP2464225B8 (en:Method) |
| JP (1) | JP5671040B2 (en:Method) |
| KR (1) | KR101494055B1 (en:Method) |
| CN (1) | CN102548406B (en:Method) |
| CA (1) | CA2771988C (en:Method) |
| ES (1) | ES2548575T3 (en:Method) |
| MX (1) | MX2012003063A (en:Method) |
| WO (1) | WO2011035161A1 (en:Method) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122444A1 (en) * | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| WO2015059467A1 (en) * | 2013-10-22 | 2015-04-30 | SETNA, Rohan | Rose bengal for detection of oxidative decomposition of contaminants |
| JP7015232B2 (ja) * | 2018-11-21 | 2022-02-02 | 東レ・ファインケミカル株式会社 | 高純度のフルオレセイン類化合物の製造方法 |
| CN113454088A (zh) * | 2019-02-26 | 2021-09-28 | 豪夫迈·罗氏有限公司 | 用于制备(6S)-3-[(4S)-4-氰基-2-氧代-吡咯烷-1-基]-6-甲基-N-(3,4,5-三氟苯基)-6,7-二氢-4H-吡唑并[1,5-a]吡嗪-5-甲酰胺的方法 |
| US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
| EP4103283A4 (en) * | 2020-03-26 | 2024-02-28 | Provectus Pharmatech, Inc. | NEW USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY |
| WO2024206220A1 (en) * | 2023-03-29 | 2024-10-03 | Provectus Pharmatech, Inc. | Anti-bacterial effect of halogenated fluoresceins against colistin-resistant gram-negative bacteria |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE108838C (en:Method) | ||||
| US1965842A (en) * | 1931-11-21 | 1934-07-10 | Nat Aniline & Chem Co Inc | Production of hydroxybenzenephthaleins |
| US1931049A (en) * | 1931-11-21 | 1933-10-17 | Nat Aniline & Chem Co Inc | Process of making dihydroxyfluoranes |
| US3829440A (en) * | 1972-12-21 | 1974-08-13 | Richardson Merrell Inc | Xanthene derivatives |
| SU517222A1 (ru) | 1974-10-25 | 1977-06-25 | Институт Биофизики Министерства Здравохранения Ссср | Способ получени препарата бенгальска роза, меченного радиоизотопами йода |
| SU792878A1 (ru) | 1978-08-29 | 1982-02-07 | Ленинградский институт ядерной физики им. Б.П.Константинова | Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом йода |
| EP0050684B1 (en) | 1980-10-27 | 1986-01-22 | Syva Company | Novel ether substituted fluorescein compounds as fluorescers and quenchers |
| SU992516A1 (ru) | 1981-06-11 | 1983-01-30 | Ленинградский Институт Ядерной Физики Им.Б.П.Константинова | Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом иода -123 |
| ES8606451A1 (es) | 1985-10-28 | 1986-04-16 | Zoster Sa | Procedimiento para la obtencion de la eritrosina sodica |
| IN168346B (en:Method) | 1987-09-07 | 1991-03-16 | Council Scient Ind Res | |
| US5637733A (en) * | 1995-09-27 | 1997-06-10 | Warner-Jenkinson Company, Inc. | Syntheses of fluorescein compounds with excess resorcinol as a solvent |
| EP0862741B1 (en) * | 1995-10-23 | 2001-04-25 | Novartis AG | Optical sensor system for the determination of ph values independently of ionic strength |
| US6162931A (en) | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
| US5945526A (en) * | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
| US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US6372907B1 (en) * | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| US6448407B1 (en) | 2000-11-01 | 2002-09-10 | Pe Corporation (Ny) | Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis |
| AU2002256991A1 (en) * | 2001-02-05 | 2002-08-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein |
| US6800765B2 (en) * | 2001-08-02 | 2004-10-05 | Molecular Devices Corporation | Fluorescent pH indicators for intracellular assays |
| CA2490961A1 (en) * | 2002-07-01 | 2004-01-08 | Guava Technologies, Inc. | Fluorescent dyes, energy transfer couples and methods |
| FR2846331B1 (fr) * | 2002-10-29 | 2006-11-17 | Synth Innove Lab | Phtaleines de purete elevee et leur procede de preparation |
| US7008759B2 (en) * | 2003-02-28 | 2006-03-07 | Polaroid Corporation | Dyes and use thereof in imaging members and methods |
| CA2570687C (en) * | 2004-06-10 | 2013-07-09 | Xantech Pharmaceuticals, Inc. | Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents |
| WO2007149456A2 (en) * | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| GB0613287D0 (en) * | 2006-07-05 | 2006-08-16 | Ge Healthcare Ltd | Dye imaging agents |
| ITMI20061713A1 (it) * | 2006-09-08 | 2008-03-09 | St Microelectronics Srl | Procedimento per la sintesi di derivati alogenati della fluoresceina utili nella produzione di dispositivi di memoria non volatile |
-
2010
- 2010-09-17 JP JP2012529937A patent/JP5671040B2/ja active Active
- 2010-09-17 ES ES10817918.5T patent/ES2548575T3/es active Active
- 2010-09-17 MX MX2012003063A patent/MX2012003063A/es unknown
- 2010-09-17 EP EP10817918.5A patent/EP2464225B8/en active Active
- 2010-09-17 CN CN201080041506.7A patent/CN102548406B/zh active Active
- 2010-09-17 US US12/884,833 patent/US8530675B2/en active Active
- 2010-09-17 KR KR1020127009834A patent/KR101494055B1/ko active Active
- 2010-09-17 WO PCT/US2010/049341 patent/WO2011035161A1/en not_active Ceased
- 2010-09-17 CA CA2771988A patent/CA2771988C/en active Active
-
2013
- 2013-06-12 US US13/916,408 patent/US9422260B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9422260B2 (en) | 2016-08-23 |
| KR20120091088A (ko) | 2012-08-17 |
| HK1172212A1 (zh) | 2013-04-19 |
| EP2464225B8 (en) | 2017-08-23 |
| WO2011035161A1 (en) | 2011-03-24 |
| CA2771988C (en) | 2016-07-05 |
| EP2464225B1 (en) | 2015-09-16 |
| KR101494055B1 (ko) | 2015-02-16 |
| EP2464225A1 (en) | 2012-06-20 |
| US20110071217A1 (en) | 2011-03-24 |
| EP2464225A4 (en) | 2013-03-27 |
| CA2771988A1 (en) | 2011-03-24 |
| CN102548406B (zh) | 2015-04-08 |
| MX2012003063A (es) | 2012-07-25 |
| CN102548406A (zh) | 2012-07-04 |
| JP5671040B2 (ja) | 2015-02-18 |
| US20130274322A1 (en) | 2013-10-17 |
| US8530675B2 (en) | 2013-09-10 |
| HK1172501A1 (en) | 2013-04-26 |
| JP2013505261A (ja) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| ES2655911T3 (es) | Compuestos de tetraciclina sustituidos con C7-fluoro | |
| ECSP066688A (es) | Polimorfo cristalino de una sal de bisulfato de underivados de azepinoindol como agentes farmaceuticos antagonista del receptor de trombina | |
| CL2009000089A1 (es) | Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras. | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| MY165906A (en) | Phenothiazine diaminium salts and their use | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
| AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| AR067346A1 (es) | Derivados de bencimidazol | |
| CO6251288A2 (es) | Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical | |
| MA34965B1 (fr) | Procédé de production de dérivé de dihydrobenzofurane optiquement actif | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| MX340572B (es) | Proceso para la fabricacion de compuestos farmaceuticamente activos. | |
| MX2011009807A (es) | Compuestos. | |
| ECSP088368A (es) | Derivados de 3-alquil-5-(4-alquil-5-oxo-tetrahidrofuran-2-il)-pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina | |
| UY31367A1 (es) | Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| ECSP099708A (es) | Nuevos métodos | |
| ECSP14013296A (es) | Derivados de etinilo | |
| AR074558A1 (es) | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 | |
| MA33027B1 (fr) | Nouveau procede de synthese de l'ivabradine zet de ses sels d'addition a un acide pharmaceutiquement acceptable | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| CO7400864A2 (es) | Moduladores selectivos del receptor de andrógenos novedosos |